Akorn acquires eye drop solutions from Merck in $52.8M deal
Akorn acquires eye drop solutions from Merck in $52.8M deal
Niche generic maker Akorn rises after announcing the acquisition of the U.S. rights to AzaSite, COSOPT, COSOPT PF (they're all eye drop solutions) from Merck for $52.8M.The move "further expands [our] position as a leader in U.S. ophthalmology products," AKRX CEO Raj Rai says.For MRK, the deal is consistent with its "ongoing strategy to sharpen commercial focus and improve operational effectiveness." (PR)
Source: seekingalpha
Boutique executive search services with best in class global network, contacts and market mastery.
Deeply connected and engaged personal service approach, long-term investment in client community and 25 year history of strong relations with both Multi-National leaders and Private Equity partners.